ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Chemistry service provider Albany Molecular Research Inc. has agreed to acquire ComGenex, a privately held drug discovery services company in Budapest, Hungary. ComGenex was founded in 1992 and had contract revenue of about $8.5 million last year. It employs 119 people, including 88 scientific and technical staff. According to AMRI, ComGenex combines parallel synthesis with computational chemistry to create libraries of small molecules with druglike characteristics. AMRI CEO Thomas E. D'Ambra notes that ComGenex is based in a European Union member state "with a significantly lower cost structure than Western European countries."
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X